ITEMS IN AFP WITH KEYWORD:
Albuterol does not improve any clinical outcomes in the outpatient or inpatient setting and should not be used in the treatment of bronchiolitis in a child 24 months or younger.
A 45-year-old man presented with worsening left-sided, sharp pleuritic chest pain that began one week earlier.
When is it benign, and which tests are indicated?
Office-based pulmonary function testing, also known as spirometry, is a powerful tool for primary care physicians to diagnose and manage respiratory problems. An obstructive defect is indicated by a low forced expiratory volume in one second/forced vital capacity (FEV1/FVC) ratio, which is defined a...
Photo Quiz presents readers with a clinical challenge based on a photograph or other image.
Aug 1, 2012 Issue
Risk Stratification of Children with Bronchiolitis [Point-of-Care Guides]
Bronchiolitis is a common and sometimes serious viral lower respiratory tract infection in young children.
Acute respiratory distress syndrome manifests as rapidly progressive dyspnea, tachypnea, and hypoxemia. Diagnostic criteria include acute onset, profound hypoxemia, bilateral pulmonary infiltrates, and the absence of left atrial hypertension. Acute respiratory distress syndrome is believed to occur ...
Bronchopulmonary dysplasia (BPD) is a major morbidity in very preterm infants that negatively affects neurodevelopmental outcomes and is resistant to therapeutic interventions. A 2002 American Academy of Pediatrics (AAP) policy statement determined that the routine use of dexamethasone to prevent or...
May 1, 2011 Issue
Effectiveness of Bronchodilators for Bronchiolitis Treatment [Cochrane for Clinicians]
Bronchodilators may transiently improve the clinical status of infants with bronchiolitis and no prior history of wheezing. However, moderately strong evidence shows that key outcomes such as oxygen saturation, need for hospitalization, length of hospitalization, and duration of symptoms are not changed by the use of bronchodilators.
The American College of Chest Physicians (ACCP) wrote a consensus statement to influence clinical practice and provide suggestions regarding the management of dyspnea in patients with advanced lung or heart disease.